Skip to main content
Table of Contents
Print

Are Cannabis-Based Medicines Officially ApprovedĀ forĀ Depression?Ā 

Author: Dr. Clarissa Morton, PharmD

At present, there are noĀ approved cannabis medicines for depressionĀ Ā in the UK. While research into cannabinoids is expanding, regulators have notĀ authorisedĀ these treatments for routine use in mental health. The absence ofĀ clear evidenceĀ from large trials means that cannabis is not currently listed amongĀ recognisedĀ therapies for depression.Ā 

Instead, medical cannabis prescriptions are restricted to certain conditions such as severe epilepsy, multiple sclerosis-related spasticity, and treatment-resistant nausea in chemotherapy. This limited scope reflects the cautious stance taken by health authorities, who are waiting for more robust studies before considering broader approval. 

Current Regulatory Position 

The official position on approved cannabis medicines for depression remains shaped by concerns over evidence quality. Below are the key regulatory considerations often raised in this discussion. 

Regulatory Approval 

So far, there is no regulatory approval for cannabis products in depression care. Authorities such as the MHRA and NICE require large, well-controlled trials before recommending new treatments, and the existing data has not yet met that standard. 

Licensed Indications 

Current licensed indications for cannabis-based medicines focus only on physical health conditions. Depression does not fall under these categories, leaving clinicians to rely on conventional therapies like talking treatments and antidepressants. 

Medical Cannabis 

Although medical cannabis is prescribed in the UK, it is done so under strict criteria and on a case-by-case basis. Mental health conditions, including depression, are not currently considered eligible for these prescriptions. 

In summary, approved cannabis medicines for depression are not yet available. Research continues, but until stronger evidence emerges, cannabis remains outside official depression care. 

For patients wondering how these restrictions may apply to them, providers likeĀ LeafEaseĀ can offer confidential consultations to explore safe andĀ appropriate options.Ā 

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Medical CannabisĀ and Depression.Ā 

Dr. Clarissa Morton, PharmD
Author

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.Ā 

Categories